The trademark application Reblozyl was filed by Celgene Corporation, a U.S. corporation (the "Applicant"). The application was published for oppositions on December 18, 2023, and it was registered by office on March 26, 2024 without any oppositions.
The application was filed in English (Italian was selected as the second language).
Change of name and professional address of the trademark registration was recorded on January 11, 2024. Change of name and address of the trademark registration was recorded on March 21, 2024.